Group 1 - Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of therapeutic biologics aimed at selectively engaging and modulating disease-specific T cells for cancer and autoimmune disease treatment [1][3] - The company will host a conference call and webcast on April 15, 2025, at 4:30 p.m. ET to provide a business update [1][2] - Cue Biopharma's proprietary platform, Immuno-STAT™, is designed to harness the body's immune system by selectively modulating disease-specific T cells without broad systemic immune modulation [3] Group 2 - The company is headquartered in Boston, Massachusetts, and is led by a management team with expertise in immunology, protein engineering, and clinical development of protein biologics [4] - Investors can access the conference call via specific phone numbers and a webcast link, with the archived version available for 30 days [2]
Cue Biopharma to Host Business Update Call and Webcast